Annexon, Inc.

Company Overview

Business Model: Annexon, Inc. is a biopharmaceutical company focused on advancing targeted immunotherapies for complement-mediated neuroinflammatory diseases. The company's core value proposition lies in its proprietary platform designed to block the classical complement pathway at its initiation by targeting C1q. This approach aims to suppress excessive or aberrant classical complement activity, which contributes to chronic inflammation and tissue damage, with the goal of slowing or halting disease progression. Annexon, Inc. seeks to preserve the beneficial immune functions of the lectin and alternative complement pathways. The company holds worldwide development and commercialization rights, including through exclusive licenses, to all of its product candidates.

Market Position: Annexon, Inc. is a clinical-stage company with no products approved for commercial sale, operating in the highly competitive pharmaceutical, biopharmaceutical, and biotechnology industries. The company is advancing two late-stage registrational programs: tanruprubart for Guillain-Barré Syndrome (GBS) and vonaprument for geographic atrophy (GA). GBS is an acute, rare, neuromuscular emergency affecting approximately 150,000 people worldwide annually, with no FDA-approved therapies. GA is a leading cause of blindness affecting over eight million people worldwide, with no approved therapies specifically targeting vision preservation. Annexon, Inc. believes its C1q inhibition platform offers a unique competitive advantage and a transformative therapeutic approach, having demonstrated robust target engagement and clinical proof of concept in multiple diseases.

Recent Strategic Developments:

• tanruprubart (GBS):
  • Filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in January 2026 for the treatment of GBS.
  • The open-label FORWARD study in the U.S. and Europe is ongoing, designed to broaden Western experience with tanruprubart. Initial pharmacokinetics (PK), pharmacodynamics (PD), biomarker, and functional data are anticipated in 2026.
  • Following these data, Annexon, Inc. plans to engage with the FDA to align on the data package for a Biologics License Application (BLA) submission in 2026.
  • Granted Fast Track and orphan drug designation from the FDA, and orphan designation from the EMA for GBS.
• vonaprument (GA):
  • Completed enrollment of 659 patients in the global, sham-controlled, double-masked Phase 3 ARCHER II trial in July 2025. Topline data are planned for the fourth quarter of 2026.
  • The single-study program will be analyzed as two sub-studies in the U.S. to support a global registration path with the FDA and EMA.
  • Received Priority Medicine (PRIME) designation by the EMA, and was selected for the EMA's Product Development Coordinator Pilot launched in July 2025.
• ANX1502 (Autoimmune Conditions):
  • An enteric-coated tablet formulation is being evaluated in an ongoing proof-of-concept (POC) study in patients with cold agglutinin disease (CAD).
  • Drug levels at and exceeding the pre-defined target have been observed in fasted CAD patients. An update is planned upon study completion in 2026.

Geographic Footprint: Annexon, Inc.'s corporate headquarters are located in Brisbane, California. Clinical trials for tanruprubart in GBS have been conducted in Bangladesh and the Philippines, with an ongoing study in the U.S. and Europe. The Phase 2 ARCHER trial for vonaprument in GA had 96% of patients from the United States, and the Phase 3 ARCHER II trial is global. Product candidates tanruprubart and vonaprument are manufactured in Europe. The company has a wholly-owned subsidiary, Annexon Biosciences Australia Pty Ltd, domiciled in Australia.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no revenue)
• Operating Margin: Not applicable (no revenue)
• Net Margin: Not applicable (no revenue)

Investment in Growth:

• R&D Expenditure: $184.7 million (2025) compared to $119.4 million (2024). (Not applicable as a percentage of revenue due to no revenue).
• Capital Expenditures: $0.137 million (2025).
• Strategic Investments:
  • Increased contract manufacturing expenses by $27.1 million (133% year-over-year) to support tanruprubart global regulatory submissions and the manufacturing technology transfer of vonaprument to a commercial-ready facility.
  • Direct clinical and nonclinical outside services costs increased by $21.9 million (58% year-over-year) due to the vonaprument Phase 3 ARCHER II trial in GA and the initiation of the tanruprubart FORWARD study in GBS.
  • Compensation and personnel-related expenses (including stock-based compensation) for R&D increased by $10.0 million (28% year-over-year), driven by higher headcount.
  • Consulting and professional services expenses for R&D increased by $6.0 million (35% year-over-year), primarily due to global regulatory submissions and the ARCHER II trial.

Business Segment Analysis

Annexon, Inc. operates in one reportable segment focused on the research and development of product candidates for complement-mediated diseases. The Chief Executive Officer reviews financial information on an aggregate basis for performance evaluation and resource allocation. The company's strategic priorities and pipeline initiatives are detailed below.

tanruprubart (Guillain-Barré Syndrome)

Key Growth Drivers:

• Demonstrated a highly statistically significant 2.4-fold improvement on the GBS-disability scale (GBS-DS) at week 8 (p=0.0058) in a placebo-controlled Phase 3 trial (30 mg/kg dose).
• Showed improvements on key secondary endpoints, including early gains in Medical Research Council (MRC) sum score at day 8 (p<0.0001) and week 8 (p=0.0351), a median of 28 fewer days on mechanical ventilation through week 26 (p=0.0356), and a 31-day reduction in median time to walk independently (p=0.0211).
• Real-World Evidence (RWE) study, in collaboration with IGOS investigators, indicated faster and greater improvement in muscle strength and disability, and fewer patients requiring mechanical ventilation, compared to standard of care (IVIg or plasma exchange).
• Generally well-tolerated profile in Phase 3, with no new safety signals.

Product Portfolio:

• An investigational targeted immunotherapy designed to rapidly halt aggressive neuroinflammation and damage in GBS.
• Mechanism of action involves blocking C1q, the initiating molecule of the classical complement pathway.

Market Dynamics:

• GBS is an acute, rare, neuromuscular emergency affecting approximately 150,000 people annually worldwide.
• There are currently no FDA-approved therapies for GBS, and existing standards of care (IVIg, plasma exchange) leave significant unmet needs.
• Competitive landscape includes Hansa Biopharma AB (imlifidase, Phase 2), AstraZeneca/Alexion (SOLIRIS (eculizumab), Phase 3 did not meet primary endpoint), and argenx (efgartigimod, Phase 2 investigator-sponsored).

vonaprument (Geographic Atrophy)

Key Growth Drivers:

• In the Phase 2 ARCHER trial, vonaprument demonstrated significant, time and dose-dependent protection from vision loss, measured by BCVA ≥15-letter loss (p=0.0021 for monthly treatment).
• Reduced the risk of 15-letter vision loss by more than 70% in the Phase 2 trial.
• Showed significant preservation of central retinal photoreceptors, as indicated by reduced ellipsoid zone (EZ) loss.
• Received Priority Medicine (PRIME) designation by the EMA, and was selected for the EMA's Product Development Coordinator Pilot.

Product Portfolio:

• An investigational neuroprotective inhibitor of C1q and the classical complement cascade.
• Administered intravitreally for dry Age-related Macular Degeneration (AMD) with GA.

Market Dynamics:

• GA is a leading cause of blindness, affecting more than eight million people worldwide.
• There are no approved therapies for GA specifically targeting the preservation of vision.
• Approved competitors include Apellis (Syfovre, a C3 inhibitor) and Astellas (avacincaptad pegol, a C5 inhibitor), both approved in 2023.
• Other pipeline competitors include Regeneron (pozelimab + cemdisiran, Phase 3), Aviceda Therapeutics (AVD-104, Phase 2), Janssen (JNJ-1887, Phase 2), Novartis (iptacopan, Phase 2), and Perceive Bio (VOY-101, Phase 2).

ANX1502 (Autoimmune Conditions)

Key Growth Drivers:

• In a Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial in healthy volunteers, ANX1502 was generally well tolerated, achieved target levels of active drug, and showed supportive impact on a PD biomarker of complement activity.
• An ongoing POC study in patients with cold agglutinin disease (CAD) has observed drug levels at and exceeding the pre-defined target in fasted patients.

Product Portfolio:

• A novel oral small molecule designed to inhibit the activated form of C1s, an enzyme that initiates the classical complement cascade.
• Converts to the active compound, ANX1439, upon administration.

Market Dynamics:

• Aims to provide selective upstream classical complement inhibition with the convenience and flexibility of oral administration for chronic autoimmune conditions.
• Competitors in CAD include Sanofi (Enjaymo, approved 2022, global rights sold to Recordati), Alpine Immune Sciences, Inc. (povetacicept), and Sanofi (BIVV020, Phase 1 completed).

Next Wave Programs:

• tanruprubart for Huntington’s Disease (HD): A Phase 2 trial showed tanruprubart was generally well-tolerated, achieved full C1q target engagement in serum and cerebrospinal fluid (CSF), and stabilized disease progression. Patients with higher baseline complement activity showed rapid clinical benefit.
• tanruprubart for Amyotrophic Lateral Sclerosis (ALS): A Phase 2a signal-finding trial indicated tanruprubart was generally well-tolerated, showed rapid and sustained C1q target engagement, and reduced downstream complement markers. Exploratory analyses suggested better outcomes for recently diagnosed patients with higher baseline classical complement activation.
• ANX009 for Lupus Nephritis (LN): A Phase 1b signal-finding trial demonstrated subcutaneous ANX009 was well-tolerated, achieved plasma C1q target engagement and complement inhibition, increased free/circulating pathogenic anti-C1q antibodies (PACAs), and improved downstream complement consumption and activation markers.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None disclosed.
• Dividend Payments: Annexon, Inc. has never declared or paid, and does not anticipate declaring or paying in the foreseeable future, any cash dividends on its capital stock.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No specific commitments disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $162.051 million
• Total Lease Liabilities: $26.201 million (comprising $2.908 million current and $23.293 million non-current operating lease liabilities)
• Net Cash Position: $135.850 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile (undiscounted lease payments):
  • 2026: $5.242 million
  • 2027: $5.425 million
  • 2028: $5.615 million
  • 2029: $5.812 million
  • 2030 and thereafter: $11.173 million

Cash Flow Generation (Year Ended December 31, 2025):

• Operating Cash Flow: $(186.356) million (Net cash used in operating activities)
• Free Cash Flow: $(186.493) million (Operating cash flow minus capital expenditures)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Annexon, Inc. does not own or operate facilities for product manufacturing, storage, distribution, or testing. The company contracts with third parties for the manufacture of its product candidates. It employs personnel with extensive technical, manufacturing, analytical, and quality experience to oversee these contract manufacturing and testing activities. Manufacturing processes are subject to extensive regulatory requirements, including current Good Manufacturing Practices (cGMPs), and are regularly assessed for compliance. The supply chains for lead product candidates involve several manufacturers specializing in raw materials procurement, drug substance manufacturing, and drug product manufacturing. Annexon, Inc. operates under work order programs with Master Services and Quality agreements. The company is engaged in technology transfers, process characterization, and process validation with its current manufacturers to establish commercial manufacturing capabilities for future regulatory submissions.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturers: Third parties are utilized for raw materials, drug substance, and drug product manufacturing. Product candidates tanruprubart and vonaprument are manufactured in Europe.
• Contract Research Organizations (CROs): Engaged to conduct preclinical studies and clinical trials.
• Clinical Investigators: Medical institutions and clinical investigators are relied upon for conducting clinical trials.
• Contract Laboratories: Used for various laboratory analyses.

Facility Network:

• Corporate Headquarters: Brisbane, California, where Annexon, Inc. leases approximately 65,818 square feet of office and laboratory space. The lease term commenced in November 2021 and ends in October 2031, with an option to extend for an additional ten years.
• Manufacturing: Relies on third-party contract manufacturers, with key product candidates manufactured in Europe.
• Research & Development: Primarily conducted at the Brisbane, California facility.

Operational Metrics:

• Specific operational metrics such as capacity utilization, efficiency measures, or quality indicators are not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Annexon, Inc. currently has a small commercial organization and has not established distribution capabilities.
• If product candidates are approved, the company intends to develop a commercialization plan for the United States and other key markets, utilizing either internal infrastructure or external partnerships.
• The strategy includes pursuing independent development and commercialization in indications and markets that can be addressed with a focused sales and marketing organization.
• Annexon, Inc. plans to explore licensing agreements, collaborations, or partnerships to accelerate and expand development and commercialization by leveraging the resources of larger biopharmaceutical companies.

Customer Portfolio:

• As a clinical-stage company, Annexon, Inc. does not currently have an established customer portfolio or product revenue.
• Target patient populations for its lead product candidates include:
  • Guillain-Barré Syndrome (GBS): Approximately 150,000 people annually worldwide.
  • Geographic Atrophy (GA): More than eight million people worldwide.
  • Cold Agglutinin Disease (CAD): Patients with this autoimmune condition.
  • Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Lupus Nephritis (LN): Patients with these neurodegenerative and autoimmune disorders.

Geographic Revenue Distribution:

• Not applicable, as Annexon, Inc. has not generated any revenue from product sales.
• Clinical development activities are conducted across various geographies, including the United States, Europe, Bangladesh, and the Philippines.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical, biopharmaceutical, and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Annexon, Inc. operates in the specialized area of complement-mediated neuroinflammatory diseases, where C1q inhibition represents a novel therapeutic approach. The market for these diseases often involves significant unmet medical needs.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Guillain-Barré Syndrome (GBS):
  • Hansa Biopharma AB (imlifidase, Phase 2, Europe and United Kingdom).
  • AstraZeneca/Alexion (SOLIRIS (eculizumab), Phase 3 in Japan, did not meet primary endpoint).
  • argenx (efgartigimod, Phase 2 investigator-sponsored trial).
  • Current standard of care includes IVIg and plasma exchange.
• Geographic Atrophy (GA):
  • Apellis (Syfovre, a C3 inhibitor, FDA-approved 2023).
  • Astellas (avacincaptad pegol, a C5 inhibitor, FDA-approved 2023).
  • Regeneron (pozelimab, a C5 inhibiting monoclonal antibody, combined with cemdisiran, a C5-targeted siRNA molecule, in Phase 3 development).
  • Other complement-targeting agents in Phase 2 include Aviceda Therapeutics (AVD-104), Janssen (JNJ-1887), Novartis (iptacopan), and Perceive Bio (VOY-101).
  • Numerous other companies (e.g., Roche, Alkeus, Belite Bio, Stealth BioTherapeutics, Boehringer Ingelheim, Galimedix Therapeutics, Cognition Therapeutics, ONL Therapeutics, Ocugen, Inflammasome Therapeutics) have products in Phase 1, 2, or 3 clinical trials that do not target the complement cascade.
• Cold Agglutinin Disease (CAD):
  • Sanofi (Enjaymo, FDA-approved February 2022, global rights sold to Recordati in October 2024).
  • Alpine Immune Sciences, Inc. (povetacicept, a fusion protein).
  • Sanofi (BIVV020, Phase 1 trial completed November 2023).

Emerging Competitive Threats:

• The industry faces continuous threats from new entrants, disruptive technologies, and alternative solutions.
• Competitors with significantly greater financial resources, established market presence, and extensive expertise in research and development, manufacturing, and commercialization pose ongoing challenges.

Competitive Response Strategy:

• Annexon, Inc. aims to leverage its C1q inhibition platform to provide a transformative therapeutic approach with differentiated clinical outcomes.
• The company plans to selectively pursue both orphan and larger patient population diseases where there is clear biological evidence of classical complement activation.
• Its strategy includes maximizing the value of its product candidates through worldwide development and commercialization rights, broad intellectual property protection, and exploring strategic partnerships to accelerate and expand market access.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Limited Operating History & Significant Losses: Annexon, Inc. is a clinical-stage biopharmaceutical company with no approved products and has incurred substantial losses since inception ($206.7 million in 2025, $138.2 million in 2024), anticipating continued losses. This makes assessing future viability challenging.
• Need for Additional Financing: The company will require substantial additional financing to achieve its development and commercialization goals. Failure to obtain necessary capital on acceptable terms could force delays, reductions, or termination of product development programs. Existing capital is expected to fund operations into the second half of 2027.
• Product Development & Regulatory Approval Risks: Success is heavily dependent on the successful development, regulatory approval, and commercialization of product candidates, some of which are in early stages. C1q inhibition is a novel approach, and there is no guarantee of therapeutic effectiveness or unforeseen safety events.
• Clinical Trial Delays or Failures: Clinical testing is expensive, time-consuming, and inherently uncertain. Delays or failures can occur at any stage due to factors such as patient enrollment difficulties, regulatory disagreements on trial design, safety concerns, or manufacturing issues.
• Market Acceptance: Even if regulatory approval is obtained, product candidates may fail to achieve broad physician and patient adoption due to competitive factors, pricing, reimbursement, or physician preferences.
• Acceptance of Foreign Clinical Data: The FDA and comparable foreign regulatory authorities may not accept data from clinical trials conducted outside the United States or the applicable jurisdiction, potentially requiring additional costly and time-consuming trials.
• Competition: Annexon, Inc. faces significant competition from companies with greater financial resources, established market presence, and extensive R&D capabilities.
• Public Health Crises: Future pandemics or similar outbreaks could materially and adversely affect preclinical and clinical trials, business operations, and financial condition.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Reliance on Third-Party Manufacturers: The company relies entirely on third-party suppliers for manufacturing product candidates. The loss of these suppliers or their failure to comply with regulatory requirements, provide sufficient quantities, or maintain acceptable quality levels could materially and adversely affect the business.
• Supply Chain Complexity: The supply chain for product candidates is complicated, involving multiple manufacturers for raw materials, drug substance, and drug product, which is expected to grow more complex with further development.
• Reliance on Third Parties for Clinical Trials: The company depends on medical institutions, clinical investigators, contract laboratories, and CROs to conduct preclinical studies and clinical trials. Failure of these third parties to perform their contractual duties or comply with regulations could delay or terminate development.
• Hazardous Materials: Business operations involve the controlled storage, use, and disposal of hazardous materials. Non-compliance with environmental laws or accidental contamination could lead to costly clean-up, liabilities, and operational disruptions.

Financial & Regulatory Risks

Market & Financial Risks:

• Fluctuating Operating Results: Quarterly and annual results of operations may fluctuate significantly due to the timing and cost of R&D activities, clinical trial progress, manufacturing costs, and regulatory approvals.
• Product Liability: An inherent risk exists from clinical testing and potential commercialization. Product liability lawsuits could result in substantial liabilities, limit commercialization, or damage the company's reputation.
• Coverage and Reimbursement: Commercial success depends on adequate coverage and reimbursement from governmental authorities and health insurers. Increasing scrutiny over drug pricing and cost-containment initiatives could limit pricing and revenue.
• Healthcare Legislation: Enacted and future healthcare legislation (e.g., the Patient Protection and Affordable Care Act, the One Big Beautiful Bill Act, Medicare Drug Price Negotiation Program) could increase costs, make obtaining marketing approval more difficult, and affect product pricing.
• Generic and Biosimilar Competition: If small molecule product candidates obtain regulatory approval, they may face generic competition sooner than anticipated under the Hatch-Waxman Act. Biologic products may face biosimilar competition under the Biologics Price Competition and Innovation Act (BPCIA).

Regulatory & Compliance Risks:

• Ongoing Regulatory Scrutiny: Even if product candidates receive regulatory approval, they will remain subject to pervasive and continuing regulation by the FDA and comparable foreign authorities, including requirements for manufacturing, labeling, promotion, and post-marketing studies. Non-compliance could lead to sanctions or market withdrawal.
• Healthcare Regulatory Laws: Business operations and relationships are subject to various healthcare regulatory laws, including fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act), HIPAA, Physician Payments Sunshine Act, and the U.S. Foreign Corrupt Practices Act. Violations could lead to significant penalties.
• Data Privacy and Security: The company processes sensitive data and is subject to numerous evolving data protection laws (e.g., HIPAA, CCPA, EU GDPR, UK GDPR). Actual or perceived failure to comply could lead to government enforcement actions, penalties, private litigation, and reputational harm. Cross-border data transfer mechanisms are subject to legal challenges.
• AI/Automated Decision-Making Technologies: The use of generative AI and/or automated decision-making technologies by personnel could result in additional compliance costs, regulatory investigations, and lawsuits.

Geopolitical & External Risks

Geopolitical Exposure:

• International Trade Policies: Operations in a global economy, including reliance on third-party suppliers outside the U.S., expose the company to risks from changes in international trade policies, tariffs, sanctions, and trade barriers, which could increase expenses and disrupt supply chains.
• Natural Disasters: Corporate headquarters and other facilities in the San Francisco Bay Area are vulnerable to earthquakes, wildfires, or other natural disasters. Limited disaster recovery plans and lack of specific insurance (e.g., earthquake, biological/hazardous waste) could lead to substantial expenses and business disruptions.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Classical Complement Pathway Inhibition: Annexon, Inc. focuses on identifying and characterizing the role of the classical complement pathway in disease, specifically targeting C1q, the initiating molecule, to block the early classical cascade and all downstream components.
• Therapeutic Areas: Research and development efforts are concentrated in autoimmune, neurodegeneration, and ophthalmology.
• Biomarker-Driven Approach: The company utilizes a precision medicine approach, evaluating biomarkers (e.g., NfL, C4a/C4 in CSF) to identify patients most likely to respond to anti-C1q therapy and inform clinical trial design.

Innovation Pipeline:

• Late-Stage Programs: tanruprubart for GBS and vonaprument for GA are the primary late-stage registrational programs.
• Oral Small Molecule: ANX1502 is a novel oral small molecule inhibiting activated C1s, aiming to provide selective upstream classical complement inhibition with oral administration convenience for chronic autoimmune conditions.
• Next Wave Programs: Supported by scientific and clinical rationale, these include tanruprubart for Huntington’s Disease (HD) and Amyotrophic Lateral Sclerosis (ALS), and ANX009 (a C1q-blocking Fab for subcutaneous delivery) for Lupus Nephritis (LN). These programs offer additional potential for portfolio growth and diversification.

Intellectual Property Portfolio:

• Patent Strategy: Annexon, Inc. actively seeks to obtain and maintain patent protection in the United States and internationally for its product candidates, new therapeutic approaches, and potential indications.
• Patent Holdings (as of March 13, 2026): The portfolio comprises 19 different patent families.
  • Stanford University License: Exclusively licenses one patent family from Stanford University, including nine granted U.S. patents covering methods of treating neurodegeneration by inhibiting the C1 complex or its components (e.g., anti-C1q antibody), expiring between 2026 and 2030.
  • Owned Anti-C1q Antibodies: Owns two patent families directed to anti-C1q antibodies (covering tanruprubart, vonaprument, ANX009), including seven granted U.S. patents, two pending U.S. applications, 34 granted foreign patents, and four pending foreign applications, expiring between 2034 and 2037.
  • Other Owned Patent Families: Includes patents and applications for vonaprument-specific claims (expiring 2036-2038), pharmaceutical formulations comprising anti-C1q antibodies (expiring 2043), small molecule modulators of the classical pathway (covering ANX1502, expiring 2041), other small molecule modulators (expiring 2043), and a dosing regimen for tanruprubart (expiring 2046).
  • Jointly Owned Patents: Owns or jointly owns 11 patent families with partners (e.g., University of California, The J. David Gladstone Institutes) directed to compositions or treatments using anti-C1q antibodies (covering tanruprubart, vonaprument, ANX009), expiring between 2034 and 2043.
• Licensing Programs: The exclusive licensing agreement with Stanford University involves an upfront payment, annual license maintenance fees, milestone payments up to $675,000, low single-digit royalties on worldwide net sales, and a portion of sublicensing income in the low double-digit percentages.
• IP Litigation: The company acknowledges the risk of costly and unpredictable litigation challenging the inventorship, ownership, validity, or enforceability of its patents and other intellectual property.

Technology Partnerships:

• Strategic alliances and research collaborations include an exclusive licensing agreement with The Board of Trustees of the Leland Stanford Junior University.
• Joint ownership of certain patent rights with The J. David Gladstone Institutes, Fondazione Telethon, Universita’ degli Studi di Trento, and the University of California.
• Collaboration with IGOS investigators for Real-World Evidence studies in GBS.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's success depends on its ability to attract, retain, and motivate highly qualified management and clinical and scientific personnel. Competition for such personnel in the biopharmaceutical field is intense.

Board Composition: The board of directors oversees cybersecurity risk management. The audit committee advises on cybersecurity risk management processes. The board is classified with three-year staggered terms, and there is no cumulative voting in director elections. The board has the exclusive right to elect directors to fill vacancies and can authorize preferred stock issuance or alter bylaws without stockholder approval. Amending or repealing certain provisions of the certificate of incorporation or bylaws requires approval of at least 66 2/3% of voting shares. Stockholder action by written consent is prohibited, and special meetings can only be called by the board. The company is also subject to the anti-takeover provisions of Section 203 of the General Corporation Law of the State of Delaware (DGCL). Directors and officers are indemnified to the fullest extent permitted by Delaware law.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 96 full-time employees.
• Geographic Distribution: Most employees are based in the Brisbane, California facility, with hybrid and remote work arrangements.
• Skill Mix: 77 employees are primarily engaged in research and development activities. 35 employees hold an M.D., Ph.D., or Pharm.D. degree.

Talent Management: Acquisition & Retention:

• Future success is dependent on the ability to attract, hire, and retain qualified personnel.
• The company offers competitive compensation (including salary, incentive bonus, and equity) and benefits packages.
• No employees are represented by a labor union, and employee relations are considered good.
• Additional personnel will be required as clinical development expands and commercial activities are initiated.

Diversity & Development:

• Specific diversity metrics or detailed development programs are not explicitly disclosed in the provided filing.

Culture & Engagement:

• Employee satisfaction and workplace flexibility are not explicitly detailed in the provided filing.

Environmental & Social Impact

Environmental Commitments: Climate Strategy:

• Specific climate strategy, emissions targets, carbon neutrality commitments, or renewable energy adoption strategies are not explicitly detailed in the provided filing.

Supply Chain Sustainability:

• Specific supplier engagement programs or responsible sourcing initiatives related to environmental or social impact are not explicitly detailed in the provided filing.

Social Impact Initiatives:

• Specific community investment or product social benefit applications are not explicitly detailed in the provided filing.

Business Cyclicality & Seasonality

Demand Patterns:

• As a clinical-stage biopharmaceutical company with no approved products, specific demand patterns or seasonal trends for its products are not applicable.
• The company acknowledges that its business is susceptible to general conditions in the global economy and financial markets, including volatility, inflation, interest rates, and potential recessions. A weak or declining economy could strain manufacturers or suppliers, potentially leading to supply disruptions, or cause customers to delay payments for future products.

Planning & Forecasting:

• Specific details on demand forecasting, inventory management, or capacity planning related to business cyclicality or seasonality are not explicitly disclosed in the provided filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Annexon, Inc. is subject to extensive regulation by the FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries. This regulation covers all aspects of product development, from research and development to manufacturing, quality control, approval, marketing, and post-approval monitoring.
• U.S. Biologics Regulation: Product candidates are regulated under the federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA), requiring a Biologics License Application (BLA) process for approval.
• Clinical Trials: Preclinical studies must comply with Good Laboratory Practice (GLP) requirements, and human clinical trials must adhere to Good Clinical Practice (GCP) requirements, including Institutional Review Board (IRB) approval and informed consent.
• FDA Review Process: Involves submission of a BLA, user fees, a 60-day filing review, and a standard 10-month (or 6-month priority) review period, potentially including Advisory Committee review and inspections of manufacturing facilities (cGMPs) and clinical sites (GCP).
• Expedited Programs: tanruprubart has received Fast Track designation from the FDA for GBS, and vonaprument has received Priority Medicine (PRIME) designation from the EMA for GA.
• Orphan Drug Designation: tanruprubart has Orphan Drug designation for GBS and HD in the U.S., and for GBS in Europe. vonaprument has PRIME designation for GA in the EU. These designations can provide market exclusivity (7 years in U.S., 10 years in EU) if the product is the first to be approved for the designated indication, subject to certain conditions.
• Post-Approval Requirements: Approved products are subject to ongoing regulatory requirements, including record-keeping, adverse event reporting, periodic reporting, product sampling and distribution, and restrictions on advertising and promotion. Post-marketing studies (Phase 4) or Risk Evaluation and Mitigation Strategies (REMS) may be required.
• Biosimilars and Exclusivity: The Biologics Price Competition and Innovation Act (BPCIA) provides an abbreviated approval pathway for biosimilar products, granting 4 years of data exclusivity and 12 years of market exclusivity to the reference biological product. Small molecule products, if developed, could face generic competition under the Hatch-Waxman Act.
• Other Healthcare Laws: The company's operations are subject to various U.S. federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act), data privacy laws (e.g., HIPAA, Physician Payments Sunshine Act), and anti-corruption laws (e.g., U.S. Foreign Corrupt Practices Act).

Trade & Export Controls:

• Annexon, Inc. is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, and anti-money laundering laws and regulations. Compliance with these standards is critical, and violations can lead to substantial civil and criminal fines, penalties, loss of export/import privileges, and reputational harm.

Legal Proceedings:

• Annexon, Inc. is not currently a party to any material legal proceedings. However, in the ordinary course of business, it may face various claims, including those related to product liability, intellectual property, and employment matters.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Not applicable, as the company has incurred net losses for all periods presented.
• Geographic Tax Planning: Not explicitly detailed in the provided filing.
• Tax Reform Impact:
  • Subject to Sections 382 and 383 of the Internal Revenue Code, which limit the ability to use pre-change net operating loss (NOL) carryforwards and other tax attributes following an "ownership change." Ownership changes occurred in 2011, 2014, 2020, and 2023.
  • Identified $0.1 million of federal and $34.7 million of state NOLs that will expire unused due to ownership changes, and $4.3 million of federal credits that will not be utilized.
  • As of December 31, 2025, $556.1 million of federal and $191.4 million of state and local NOLs are not expected to expire unutilized due to identified ownership changes. Federal NOLs generated after December 31, 2017 ($513.2 million) carry forward indefinitely, subject to an 80% taxable income limitation.
  • As of December 31, 2025, the company had $37.4 million of federal and $10.2 million of state credit carryforwards. Federal credits begin expiring in 2031, while state credits do not expire.
  • A full valuation allowance of $224.9 million has been recorded against deferred tax assets as of December 31, 2025, as management believes it is more likely than not that these assets will not be realized.
  • The company files income tax returns in the United States, various states, and Australia. Tax years 2011 through 2025 remain effectively open for examination.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage:
  • Annexon, Inc. carries product liability insurance covering its clinical trials.
  • A directors’ and officers’ insurance policy is maintained.
  • Cyber liability insurance is maintained.
  • The company does not carry earthquake insurance.
  • Property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.
• Risk Transfer Mechanisms: Beyond insurance, specific risk transfer mechanisms are not explicitly detailed in the provided filing.